FIA
HUMA icon

FNY Investment Advisers’s Humacyte HUMA Stock Holding History

FNY Investment Advisers’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400
Closed -$1K – 744
2023
Q4 		$1K Hold
400
– – ﹤0.01% 424
2023
Q3 		$1K Hold
400
– – ﹤0.01% 561
2023
Q2 		$1K Hold
400
– – ﹤0.01% 479
2023
Q1 		$1K Hold
400
– – ﹤0.01% 509
2022
Q4 		$0 Hold
400
– – ﹤0.01% 591
2022
Q3 		$1K Hold
400
– – ﹤0.01% 583
2022
Q2 		$1K Hold
400
– – ﹤0.01% 623
2022
Q1 		$2K Sell
400
-600
-60% -$3.49K ﹤0.01% 622
2021
Q4 		$7K Buy
+1,000
New +$9.89K ﹤0.01% 412

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

FNY Investment Advisers's HUMA Position: Q1 2024 in Review

FNY Investment Advisers sold out of Humacyte (HUMA) in Q1 2024, closing a stake of 400 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in HUMA in Q4 2021 and held it in 9 quarters. The position peaked at $7K in Q4 2021. 96 funds tracked by Wall St. Rank hold HUMA as of Q1 2024.

  • FNY Investment Advisers reported no remaining Humacyte position as of Q1 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 400 Humacyte shares in Q1 2024, an estimated $1K.
  • FNY Investment Advisers first reported a position in Humacyte in Q4 2021 and held it in 9 quarters.
  • FNY Investment Advisers's Humacyte position peaked at $7K in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Humacyte as of Q1 2024.

Based on FNY Investment Advisers's 13F filing for Q1 2024, filed 3 May 2024.